{
    "nct_id": "NCT04345367",
    "official_title": "A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
    "inclusion_criteria": "* 18 years of age or older\n* Diagnosis of chronic atopic dermatitis (AD) for at least 6 months\n* Moderate to severe AD (BSA at least 10%, IGA at least 3, EASI at least 16, and PP-NRS severity score at least 4)\n* Recent history of inadequate response to treatment with medicated topical therapy for AD, or who have required systemic therapies for control of their disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation\n* Have increased risk of developing venous thromboembolism\n* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study\n* Prior treatment with systemic JAK inhibitors or IL-4 or IL-13 antagonists including dupilumab, lebrikizumab or tralokinumab\n* Other active non-AD inflammatory skin diseases or conditions affecting skin\n* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator\n* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception",
    "miscellaneous_criteria": ""
}